Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Adam J Byrne

Showing results (1-10 of 36) with videos related to

Pageof 4
Sort By:
Mucosal Immunology|November 13, 2020
Macrophage metabolic reprogramming during chronic lung diseasePatricia P Ogger, Adam J Byrne
The Journal of Pathology|June 9, 2020
Lung fibrosis enters the iron age<sup>†</sup>Patricia P Ogger, Adam J Byrne
Clinical and Experimental Immunology|November 29, 2023
Itaconate as a key regulator of respiratory diseaseChristina Michalaki, Gesa J Albers, Adam J Byrne
Frontiers in Immunology|October 11, 2023
Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosisVipin Kumar, Marc Hertz, Albert Agro, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Synthesis and pharmacological evaluation of the individual stereoisomers of 3-[methyl(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-indanone, a potent mast cell stabilising agentAdam J Byrne, James W Barlow, John J Walsh
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2011
Cutting edge: histamine is required for IL-4-driven eosinophilic allergic responsesJulie A Swartzendruber, Adam J Byrne, Paul J Bryce
Trends in Molecular Medicine|March 17, 2016
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?Adam J Byrne, Toby M Maher, Clare M Lloyd
Thorax|August 20, 2015
Pulmonary macrophages: key players in the innate defence of the airwaysAdam J Byrne, Sara A Mathie, Lisa G Gregory, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 14, 2011
Novel mast cell-stabilising amine derivatives of 3,4 dihydronaphthalen-1(2H)-one and 6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-oneJames W Barlow, Tao Zhang, Orla Woods, et al.
Immunotherapy Advances|September 20, 2021
A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapyLaura J Pallett, Sarah Dimeloe, Linda V Sinclair, et al.
Pageof 4

Showing results (1-10 of 36) with videos related to

Sort By:
Pageof 4
Mucosal Immunology|November 13, 2020
Macrophage metabolic reprogramming during chronic lung diseasePatricia P Ogger, Adam J Byrne
The Journal of Pathology|June 9, 2020
Lung fibrosis enters the iron age<sup>†</sup>Patricia P Ogger, Adam J Byrne
Clinical and Experimental Immunology|November 29, 2023
Itaconate as a key regulator of respiratory diseaseChristina Michalaki, Gesa J Albers, Adam J Byrne
Frontiers in Immunology|October 11, 2023
Type 1 invariant natural killer T cells in chronic inflammation and tissue fibrosisVipin Kumar, Marc Hertz, Albert Agro, et al.
Bioorganic & Medicinal Chemistry Letters|January 29, 2011
Synthesis and pharmacological evaluation of the individual stereoisomers of 3-[methyl(1,2,3,4-tetrahydro-2-naphthalenyl)amino]-1-indanone, a potent mast cell stabilising agentAdam J Byrne, James W Barlow, John J Walsh
Journal of Immunology (Baltimore, Md. : 1950)|December 14, 2011
Cutting edge: histamine is required for IL-4-driven eosinophilic allergic responsesJulie A Swartzendruber, Adam J Byrne, Paul J Bryce
Trends in Molecular Medicine|March 17, 2016
Pulmonary Macrophages: A New Therapeutic Pathway in Fibrosing Lung Disease?Adam J Byrne, Toby M Maher, Clare M Lloyd
Thorax|August 20, 2015
Pulmonary macrophages: key players in the innate defence of the airwaysAdam J Byrne, Sara A Mathie, Lisa G Gregory, et al.
Medicinal Chemistry (Shariqah (United Arab Emirates))|April 14, 2011
Novel mast cell-stabilising amine derivatives of 3,4 dihydronaphthalen-1(2H)-one and 6,7,8,9-tetrahydro-5H-benzo[7]annulen-5-oneJames W Barlow, Tao Zhang, Orla Woods, et al.
Immunotherapy Advances|September 20, 2021
A glutamine 'tug-of-war': targets to manipulate glutamine metabolism for cancer immunotherapyLaura J Pallett, Sarah Dimeloe, Linda V Sinclair, et al.
Pageof 4